Similarly to our in vitro data with ZEGFR:03115–IR700DX, in vivo imaging studies demonstrated that the conjugate penetrates deeply in the EGFR highly expressing U87‐MGvIII subcutaneous and orthotopic tumors, allowing for clear tumor visualization as early as 1 h post‐injection. The gene discussed is EGFR; the disease is neoplasm.